Nature Medicine retracts China lung cancer immunotherapy timing paper, citing data integrity concerns — and the fallout could fuel US anti-China sentiment in biopharma.
Nature Medicine has retracted a high-profile paper it published in February detailing the results of a China-based trial suggesting that cancer
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account